Mankind Pharma Limited
Against an issue price of ₹1,080. Split- and bonus-adjusted official closes — a past move, never a forecast.
Mankind Pharma Limited was a mainboard initial public offer.
The book was open from 25 April 2023 to 27 April 2023.
The issue was priced at ₹1,080 a share, from a band of ₹1,026 to ₹1,080.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 9 May 2023.
The last official close on file is ₹2,504 (30 September 2026), which is 131.8% above the issue price.
It now trades as MANKIND, and its filed financials are on its company page.
Shares sold in the issue at ₹1,080 last closed at ₹2,503.8.
See MANKIND’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- Registrar
- KFin Technologies Limited
- Lead managers
- Kotak Mahindra Capital Company Limited
- Axis Capital Limited
- IIFL Securities Limited
- Jefferies India Private Limited
- J.P. Morgan India Private Limited
- Bidding opens25 Apr 2023
- Bidding closes27 Apr 2023
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing9 May 2023
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment9 Nov 2023already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment9 Nov 2024already free
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Weighted-average return on net worth over the same years: 25.51%.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Abbott India Limited | 56.2 | — | 28.3% | 375.86 | ₹49,193 cr |
| Alkem Laboratories Limited | 23.0 | — | 19.1% | 137.63 | ₹1,06,342 cr |
| Cipla Limited | 28.2 | — | 12.1% | 31.17 | ₹2,17,633 cr |
| Dabur India Limited | 54.6 | — | 20.8% | 9.81 | ₹1,08,887 cr |
| Eris Lifesciences Limited | 19.1 | — | 21.3% | 29.88 | ₹13,470 cr |
| GlaxoSmithKline Pharmaceuticals Limited | 57.0 | — | 63.6% | 100.04 | ₹32,780 cr |
| IPCA Laboratories Limited | 22.4 | — | 16.1% | 34.85 | ₹58,298 cr |
| JB Chemicals & Pharmaceuticals Limitednot in our universe | 39.5 | — | 18.1% | 49.82 | ₹24,242 cr |
| Procter & Gamble Health Limited | 42.3 | — | 31.2% | 116.00 | ₹11,144 cr |
| Sun Pharmaceuticals Industries Limitednot in our universe | 71.5 | — | 6.8% | 13.60 | ₹3,86,545 cr |
| Torrent Pharmaceutical Limitednot in our universe | 66.3 | — | 13.1% | 22.97 | ₹85,080 cr |
| Zydus Lifesciences Limited | 11.0 | — | 26.4% | 43.83 | ₹1,52,652 cr |
| Zydus Wellness Limited | 31.1 | — | 6.4% | 48.54 | ₹20,091 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Axis Capital Limited 2021 – 2026 | 86 18 measurable | +11.7% | 5 of 15 | 1 of 5 | 2 of 8 |
IIFL Securities Limited 2021 – 2025 | 39 2 measurable | -8.1% | 1 of 1 | — | — |
Jefferies India Private Limited 2022 – 2026 | 25 4 measurable | +21.1% | 2 of 5 | 1 of 1 | — |
J. P. Morgan India Private Limited 2022 – 2026 | 23 4 measurable | +2.6% | 2 of 4 | 0 of 1 | 0 of 1 |
Kotak Mahindra Capital Company 2021 – 2026 | 65 15 measurable | +16.6% | 3 of 14 | 1 of 3 | 2 of 4 |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Kfin Technologies Limited 2021 – 2026 | 130 37 measurable | +6.5% | 10 of 21 | 3 of 6 | 2 of 6 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive3 May 2023
- Draft red herring prospectus (DRHP)· ZIP · exchange archive15 Sept 2022
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.